News Archive

5 October 2016

Merck Animal Health Honors Recipients of World Rabies Day Health Awards

MADISON, NJ, October 5, 2016 – Merck Animal Health (known as MSD Animal Health outside the United States and Canada), is proud to announce the winners of the World Rabies Day MSD Animal Health Awards. These awards represent a partnership between Merck Animal Health and the Global Alliance for Rabies Control (GARC), a nonprofit group dedicated to preventing human deaths from rabies and relieving the burden of rabies in other animal populations, especially dogs.

The World Rabies Day MSD Animal Health Awards recognize the exemplary work to eradicate rabies around the world. Rabies causes over 59,000 deaths every year.1 The recipients of this award were nominated by their friends, peers and communities, as they have made great strides to improve both human and animal lives.

“We are proud to honor individuals who embody the company’s commitment to the Science of Healthier Animals™, we were faced with the difficult choice of choosing the winners,” states Alasdair King, director, Intergovernmental Veterinary Health, Merck Animal Health. “There was an outpouring of inspirational nominees from countries around the world including, India, Sri Lanka, Madagascar, South Africa, Brazil, Tunisia, Liberia, Croatia and more.”
  
This year’s recipients are:

  • Dr. Thinlay Bhutia, India
  • Dr. Agnes Jemutai Korir, Kenya
  • Professor Kastriot Korro, Albania
  • Dr. Sergio Recuenco-Cabrera, Peru
  • Visakha Society for Protection and Care of Animals, India
  • Liberia Animal Welfare and Conservation Society, Liberia
  • Kurdistan Organization for Animal Rights Protection, Iraq
  • Zach Jones Memorial Fund, USA

“This award is a motivation for me to work harder, to train my staff in the field of rabies and to continue teaching people how to protect themselves,” states Professor Kastriot Korro, an award recipient from Albania. “Rabies is not only one person`s issue, but an issue for many communities, and everyone should start doing their part to end rabies.”

Recipients will receive not only recognition for their dedication to control this disease with a plaque and certificate, but also $1,200 (or resources to an equal value).

To learn more about the recipients, visit https://rabiesalliance.org/awards/.

To learn more about the Global Alliance for Rabies Control, visit https://rabiesalliance.org/.

About Merck Animal Health
For 125 years, Merck has been a global health care leader working to help the world be well. Merck Animal Health, known as MSD Animal Health outside the United States and Canada, is the global animal health business unit of Merck. Through its commitment to the Science of Healthier Animals™, Merck Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.merck-animal-health.com or connect with us on LinkedIn, Facebook and Twitter at @MerckAH.

Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA 
This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. 

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2015 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

[1] Hampson K, Coudeville L, Lembo T, Sambo M, Kieffer A, Attlan M, Barrat J, Blanton JD, Briggs DJ, Cleaveland S et al. (2015) Estimating the Global Burden of Endemic Canine Rabies. PLoS Negl Trop Dis 9(4): e0003709. doi:10.1371/journal.pntd.0003709